Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Anemia, Refractory, with Excess of Blasts 24Myelodysplastic Syndromes 23Leukemia, Lymphocytic, Chronic, B-Cell 21Leukemia, Myelomonocytic, Chronic 20Hodgkin Disease 19Myeloproliferative Disorders 18Multiple Myeloma 16Lymphoma, Non-Hodgkin 16Leukemia 15Primary Myelofibrosis 14Lymphoma 14Congenital Abnormalities 14Anemia, Aplastic 14Lymphoma, Follicular 13Leukemia, Myeloid, Chronic-Phase 13Leukemia, Myeloid, Accelerated Phase 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Burkitt Lymphoma 11Lymphoma, B-Cell, Marginal Zone 10Neoplasms, Plasma Cell 9Myelodysplastic-Myeloproliferative Diseases 9Lymphoma, Mantle-Cell 9Lymphoma, Large-Cell, Immunoblastic 9Lymphoma, Large B-Cell, Diffuse 9Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 9Graft vs Host Disease 9Polycythemia Vera 8Blast Crisis 8

Interventions

Cyclophosphamide 3thymoglobulin 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Tacrolimus × Classical hematology × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡